Publications:

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.

Plos One

R Romagnuolo, CA Scipione, SM Marcovina, M Gemin, NG Seidah, MB Boffa, ML Koschinsky

Publication Date: 2017

Variant appearance in text: PCSK9: L455X

PubMed Link: 28750079

Variant Present in the following documents:

• Main text

View BVdb publication page

Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

The Journal Of Biological Chemistry

K Ly, YG Saavedra, M Canuel, S Routhier, R Desjardins, J Hamelin, J Mayne, C Lazure, NG Seidah, R Day

Publication Date: 2014-06-20

Variant appearance in text: PCSK9: L455X

PubMed Link: 24808179

Variant Present in the following documents:

• Main text

View BVdb publication page

The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

The Journal Of Biological Chemistry

YG Saavedra, R Day, NG Seidah

Publication Date: 2012-12-21

Variant appearance in text: PCSK9: L455X

PubMed Link: 23105118

Variant Present in the following documents:

• Main text

View BVdb publication page

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.

Journal Of Lipid Research

ØL Holla, J Cameron, K Tveten, TB Strøm, KE Berge, JK Laerdahl, TP Leren

Publication Date: 2011-10

Variant appearance in text: PCSK9: L455X

PubMed Link: 21771976

Variant Present in the following documents:

• Main text

View BVdb publication page

Alternative transcript annotations: